Program
Palovarotene
Also written as “Palovarotene dose level 1”, “Palovarotene dose level 2” and “Palovarotene dose level 3”.
Its studies are mostly in Myositis Ossificans · Dry Eye Syndromes, led by Ipsen.
Furthest: phase 3, since Oct 9, 201710 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ipsen | 100 open or running | phase 3since Oct 9, 2017 | Jul 13, 2014 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 13, 2014First study: phase 2 study in Myositis OssificansFirst studyNCT02190747 · 40 enrolled · United States, France, United Kingdom
- Oct 26, 2014Phase 2 study in Myositis OssificansNCT02279095 · 58 enrolled · United States, Argentina, Australia and more
- Aug 6, 2015Phase 2 study in Myositis OssificansNCT02521792 · 6 enrolled · United States
- Oct 9, 2017Phase 3 study in Myositis OssificansNCT03312634 · 107 enrolled · United States, Argentina, Australia and more
- Oct 11, 2017Phase 2 study in Exostoses, Multiple HereditaryNCT03442985 · 193 enrolled · United States, Australia, Belgium and more
- Feb 18, 2021Phase 1 study in Dry Eye SyndromesNCT04762355 · 48 enrolled · Canada
- Apr 1, 20212 phase 1 studiesNCT04829786, NCT04829773
- Aug 25, 2021Phase 3 study in Myositis OssificansNCT05027802 · 61 enrolled · United States, Argentina, Australia and more
- Mar 24, 2025Phase 1 study in Hepatic ImpairmentNCT06908954 · 31 enrolled · United States
TargetBeta
RARG →read by rule
“Retinoic acid receptor gamma agonist”ChEMBL 37, by rule
Other programs on RARG
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| trifarotenerule | Galderma Group | phase 4 | 13 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06908954Hepatic Impairment · United States | 1 | Completed | Feb 6, 2026 | 31 |
| NCT05027802Myositis Ossificans · United States, Argentina, Australia and more | 3 | Completed | Nov 30, 2024 | 61 |
| NCT04829786FOP | 1 | Completed | Oct 23, 2015 | 18 |
| NCT04829773Myositis Ossificans · United States | 1 | Completed | Mar 29, 2019 | 48 |
| NCT04762355Dry Eye Syndromes · Canada | 1 | Completed | Jan 3, 2019 | 48 |
| NCT03442985Exostoses, Multiple Hereditary · United States, Australia, Belgium and more | 2 | Terminated | Mar 24, 2020 | 193 |
| NCT03312634Myositis Ossificans · United States, Argentina, Australia and more | 3 | Completed | Jan 24, 2020 | 107 |
| NCT02521792Myositis Ossificans · United States | 2 | Terminated | Aug 4, 2016 | 6 |
| NCT02279095Myositis Ossificans · United States, Argentina, Australia and more | 2 | Completed | Sep 20, 2022 | 58 |
| NCT02190747Myositis Ossificans · United States, France, United Kingdom | 2 | Completed | May 23, 2016 | 40 |
How it is read
Names in the registry
- “Palovarotene”, 9 entries
- “Palovarotene dose level 1”, 1 entry
- “Palovarotene dose level 2”, 1 entry
- “Palovarotene dose level 3”, 1 entry
- “Palovarotene dose level 4”, 1 entry
Conditions, from the studies’ own filings
- Myositis Ossificans, 6 studies
- Dry Eye Syndromes, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.